[¹²³I]MIBG is a better early marker of anthracycline cardiotoxicity than [¹⁸F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.

ABSTRACT:

Background

During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [¹⁸F]FDG and [¹²³I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiotoxicity rat model.

Methods

Male Wistar Han rats were intravenously administered 3 times at 10 days' interval with saline or doxorubicin (5 mg/kg). [¹²³I]MIBG SPECT/CT (single photon emission computed tomography-computed tomography) and simultaneous [¹⁸F]FDG PET (positron emission tomography)/7 Tesla cardiac MR (magnetic resonance) imaging acquisitions were performed at 24 h interval before first doxorubicin / saline injection and every 2 weeks du

SUBMITTER: Oudot A 

PROVIDER: S-EPMC8452816 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature